[
  {
    "ts": null,
    "headline": "GLP-1RA developer Metsera targets $289m IPO",
    "summary": "Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.",
    "url": "https://finnhub.io/api/news?id=2a23fc60ba5f64a4da1b73626bfde9fffb589e1b57e93c59bf2b3df506056353",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738088822,
      "headline": "GLP-1RA developer Metsera targets $289m IPO",
      "id": 132830807,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/01/shutterstock_2256852825.jpg",
      "related": "NDAQ",
      "source": "Yahoo",
      "summary": "Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.",
      "url": "https://finnhub.io/api/news?id=2a23fc60ba5f64a4da1b73626bfde9fffb589e1b57e93c59bf2b3df506056353"
    }
  },
  {
    "ts": null,
    "headline": "Nasdaq, Inc. (NDAQ): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Nasdaq, Inc. (NDAQ) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on NDAQ. Nasdaq, Inc. (NDAQ)’s share was trading at $81.46 as of Jan 27th. NDAQ’s trailing and forward P/E were 48.89 and 25.91 respectively according to Yahoo Finance. Nasdaq Inc. (NDAQ) presents a […]",
    "url": "https://finnhub.io/api/news?id=d0c8949c241322e04c09156055db0175f4f32f3a3c8861af9dcfb47f0f857794",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738073844,
      "headline": "Nasdaq, Inc. (NDAQ): A Bull Case Theory",
      "id": 132830808,
      "image": "https://media.zenfs.com/en/insidermonkey.com/19f06d2f1156978c403925aa82274a77",
      "related": "NDAQ",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Nasdaq, Inc. (NDAQ) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on NDAQ. Nasdaq, Inc. (NDAQ)’s share was trading at $81.46 as of Jan 27th. NDAQ’s trailing and forward P/E were 48.89 and 25.91 respectively according to Yahoo Finance. Nasdaq Inc. (NDAQ) presents a […]",
      "url": "https://finnhub.io/api/news?id=d0c8949c241322e04c09156055db0175f4f32f3a3c8861af9dcfb47f0f857794"
    }
  }
]